- Report
- March 2024
- 193 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- February 2024
- 175 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1448EUR$1,500USD£1,242GBP
- Report
- November 2023
- 189 Pages
Global
From €4729EUR$4,900USD£4,057GBP
- Report
- March 2018
- 220 Pages
Global
From €2123EUR$2,200USD£1,821GBP
- Report
- September 2022
- 152 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- August 2022
- 120 Pages
Global
From €4343EUR$4,500USD£3,726GBP
- Drug Pipelines
- February 2022
- 60 Pages
Global
From €6752EUR$6,995USD£5,791GBP
- Report
- April 2024
- 50 Pages
Global
From €2558EUR$2,650USD£2,194GBP
- Report
- February 2024
- 168 Pages
Global
From €3475EUR$3,600USD£2,981GBP
- Report
- April 2023
- 160 Pages
Global
From €5790EUR$5,999USD£4,967GBP
Acamprosate is a drug used to treat alcohol dependence within the Central Nervous System (CNS) drug market. It works by restoring the balance of certain chemicals in the brain that are affected by alcohol use. Acamprosate is typically prescribed to individuals who have recently stopped drinking and are at risk of relapse. It is believed to reduce cravings and help maintain abstinence.
Acamprosate is available in both oral and injectable forms, and is typically taken three times a day. Common side effects include nausea, vomiting, and diarrhea. It is important to note that acamprosate should not be taken by individuals who are still drinking alcohol.
The acamprosate market is a small but growing segment of the CNS drug market. It is primarily used in the treatment of alcohol dependence, but is also being studied for its potential use in other CNS disorders.
Some companies in the acamprosate market include Merck, Pfizer, and Sanofi. Show Less Read more
